Write-ups and models on asymmetric stocks and macro themes. Built on 10+ years studying top investors/funds, and 500,000+ words of published guides.
© 2026 StableBread.
Special Situation
Robotics
+3
Sep 6, 2026
Agility will be the only listed U.S. humanoid pure-play, with a factory rated for 10,000 robots a year and paid deployments at Amazon, GXO, Schaeffler, Toyota, and Mercado Libre. However, at $13.40/share, you're paying $4.51B for just $1.78M of FY2025 revenue.
RVPH
+2
Aug 20, 2026
Reviva pushed its Phase 3 back a year, and the stock is down ~27% since my June write-up. Two developments matter more: (1) a patent filing that stretches exclusivity to 2046 and (2) evidence Teva has studied brilaroxazine since 2023.
LAES
+2
Jul 27, 2026
SEALSQ trades at $2.43, just 11% above its net cash, so you pay close to nothing for an $18M secure-chip business and get its post-quantum and quantum-computing story on top.
Semis
+3
Jul 7, 2026
A US manufacturer selling into AI memory/logic chips, photonics, and defense batteries is going public at a $1.2B valuation. It's backed by a $100M DOE grant, Samsung SDI building its factory, and a 2028 law banning the US military from buying Chinese battery cells.
RVPH
+2
Jun 18, 2026
Reviva trades below its cash and just dropped to the OTC market, but it owns a schizophrenia drug that topped Caplyta's Phase 3 numbers, the kind big pharma buys for billions
Write-ups and models on asymmetric stocks and macro themes. Built on 10+ years studying top investors/funds, and 500,000+ words of published guides.